Hints and tips:
Related Special Reports
...Investors will still have to wait until at least 2026 for an approved oncology product....
...This primes the body to recognise the virus if infected and make an immune response....
...In 2020, oncology companies received nearly $7bn in investment, an increase of 900 per cent since 2011....
...“It was one of the most epic episodes ever in pharmaceuticals history: you got an accelerated approval of a product that didn’t have a completed phase 3 trial....
...Figuring out how to design a vaccine that can teach immune cells how to recognise and combat tumours could become the next big thing in the $200bn a year oncology drug market....
...To make up for the shortfall in its pipeline, the US drugmaker earlier this year announced plans to buy Seagen, an oncology drugmaker, for $43bn; a deal Pfizer said it expected to close on Thursday....
...Moderna plans to launch products in oncology, rare and latent diseases by 2028....
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
...It expects to add $10bn-$15bn in annual sales after launching new products in oncology, rare and latent diseases by 2028....
...Teresa Graham, chief of Roche’s pharmaceutical division, said more patients suffered from diseases of the immune system than from cancer, and the current drugs did not serve them well....
...MSD helped transform cancer care with its drug Keytruda, which harnessed the immune system to tackle tumours....
...suppressing the whole immune system....
...“Our work in rearming patients’ immune systems is particularly exciting for global health since this concept has application beyond oncology and into infectious diseases such as HIV,” she said....
...The US drugmaker was reportedly in talks with oncology-focused Seagen about a potential deal last year but did not move forward with a transaction....
...Antiviral medicines target viruses in a bid to prevent them infecting healthy cells, helping immune systems fight off the infection....
...Pfizer has agreed to acquire oncology-focused biotech Seagen for a total enterprise value of $43bn as the US pharmaceutical company refills its drugs pipeline amid a sharp fall in sales of its Covid-19 products...
...Shares in oncology-focused biotech Seagen, which Pfizer has agreed to buy for $43bn, also fell amid fears the agency could target other deals in the sector....
...The oncology-focused biotech agreed a $43bn deal to be acquired by Pfizer....
...But the company is inspired by a transformation in oncology....
...The company, whose four approved oncology treatments generated $2bn in sales last year, should help the pharmaceutical company offset some of an expected decline in revenue as the Covid vaccine boom fades...
...One of the most exciting and potentially lucrative areas targeted by Moderna is in the field of oncology....
...It rejected Illumina’s claim that the acquisition would accelerate the rollout of Grail’s oncology tests and save lives, noting the company’s projections were “vague, self-serving, and unsupported”....
...Therapeutics in 2020 and its $3.8bn takeover of US-based oncology specialist OSI Pharmaceuticals in 2010....
...Denton said the company was adjusting its business development strategy after its $43bn acquisition in March of oncology-focused biotech Seagen to focus more on shareholder returns....
...directors have warned that Illumina’s battles with antitrust regulators and activist investor Carl Icahn over its ownership of the cancer screening company threaten to hamper access to potentially life-saving oncology...
International Edition